Gamma-glutamyl Transpeptidase Deficiency (Glutathionuria): Comprehensive Disease Characteristics Report

Disease: Gamma-glutamyl Transpeptidase Deficiency (Glutathionuria) MONDO ID: MONDO:0009285 · OMIM: 231950 · Category: Mendelian (autosomal recessive inborn error of metabolism) Report date: 2026-10-15

Summary

Gamma-glutamyl transpeptidase (GGT) deficiency, historically termed glutathionuria, is an ultra-rare autosomal recessive inborn error of the γ-glutamyl (glutathione) cycle caused by biallelic loss-of-function variants in GGT1 on chromosome 22q11.23. The disease was described biochemically in the 1970s–1980s but its molecular cause was only proven in 2018, when whole-genome sequencing of two affected siblings revealed a 16.9 kb homozygous intragenic deletion in GGT1, with the parents and a healthy sibling confirmed as carriers/wild-type — providing the first direct genetic evidence of autosomal recessive inheritance PMID: 29483667.

The core biochemical defect is a failure of extracellular glutathione (GSH) catabolism. GGT is a membrane-bound ectoenzyme on the apical (brush-border) surface of transport/secretory epithelia — most importantly the renal proximal tubule — where it initiates breakdown of filtered and plasma glutathione and salvages cysteine. When the enzyme is absent, glutathione cannot be reclaimed and is lost in the urine. This produces the diagnostic hallmark of glutathionuria plus glutathionemia, accompanied by elevated plasma γ-glutamylcysteine, cysteine and cysteinylglycine, with serum/tissue GGT activity that is very low or undetectable. Notably, plasma amino acid levels and renal amino acid reabsorption remain normal, demonstrating that the γ-glutamyl cycle is not essential for amino acid transport.

The human clinical phenotype is remarkably mild relative to the dramatic biochemical abnormality: fewer than ~8 patients have ever been reported, and the dominant features are neurological/cognitive (intellectual disability, developmental delay, behavioral problems), with variable, generally mild, expressivity. By contrast, Ggt1-knockout and ENU-mutant mice display a severe multisystem phenotype — growth failure, cataracts, lethargy, infertility, osteopenia and shortened lifespan — all traced to systemic cysteine/GSH depletion and all reversible with cysteine repletion (N-acetylcysteine or the cysteine prodrug L-2-oxothiazolidine-4-carboxylate, OTZ). The species discrepancy likely reflects paralog redundancy (the human GGT family has 13 homologous genes) and differences in GSH handling. No approved disease-specific therapy exists for humans; management is supportive, and prevention relies on genetic counseling and cascade testing. Mechanistic causality (cysteine depletion as the proximate cause) is proven only in the mouse model and is inferred, but not formally trialed, in humans.

1. Disease Information

Overview. GGT deficiency is a Mendelian inborn error of metabolism in which absence of the ectoenzyme gamma-glutamyl transpeptidase blocks the first step of extracellular glutathione degradation. The clinical and biochemical entity is defined by massive urinary and plasma glutathione accumulation ("glutathionuria" / "glutathionemia") in the setting of absent GGT enzyme activity.

Key identifiers.

Synonyms / alternative names: Glutathionuria; Gamma-glutamyltransferase deficiency; Gamma-glutamyl transferase deficiency; γ-GT deficiency; Glutathionemia (describes the associated plasma finding).

Source of information. The knowledge base is derived almost entirely from aggregated disease-level resources and individual published case reports (not EHR-scale data). The total human experience is fewer than ~8 patients, so the evidence is case-level, supplemented substantially by mouse model data. "A rare disease, with only six patients reported in the literature" PMID: 29483667.

2. Etiology

Primary cause — genetic. The disease is caused by biallelic loss-of-function variants in GGT1, inherited in an autosomal recessive pattern. The first molecular proof was a 16.9 kb homozygous intragenic deletion in GGT1 with a 13 bp insertion at the breakpoint identified by whole-genome sequencing in two affected siblings: "Whole-genome sequencing revealed the presence of a 16.9 kb homozygous deletion in GGT1, one of the genes encoding enzymes with γ-glutamyl transpeptidase activity in the human genome" PMID: 29483667. Earlier case series inferred autosomal recessive inheritance from reduced fibroblast GGT activity in clinically normal, presumably heterozygous, parents PMID: 6118466; PMID: 238530.

Genetic risk factors. The sole established genetic risk factor is inheritance of two pathogenic GGT1 alleles. No susceptibility loci or modifier genes have been formally established in humans (the ultra-rare case count precludes association studies). gnomAD constraint metrics indicate GGT1 is moderately intolerant to heterozygous LOF (see Section 4), yet heterozygous carriers are clinically healthy, consistent with recessive disease.

Environmental risk factors. None established. There is no evidence that toxins, lifestyle, occupational exposure, age or sex trigger or modify the primary Mendelian disease. (Separately, acquired/pharmacologic GGT inhibition can phenocopy the biochemistry: administration of γ-glutamyl amino acids or transpeptidase inhibitors induces glutathionuria in mice — relevant mechanistically but not an etiology of the inherited disease PMID: 2873573; PMID: 34150.)

Protective factors. None characterized in humans. In mice, provision of an alternative cysteine source (N-acetylcysteine, OTZ) is "protective" against the downstream consequences — not a protection against the genetic lesion itself but a bypass of its metabolic consequence.

Gene–environment interactions. Not characterized for this Mendelian disorder. Mechanistically, dietary cysteine/protein intake would be expected to modulate the severity of cysteine deficiency (as shown pharmacologically in mice), but this interaction has not been formally studied in human patients.

3. Phenotypes

The human phenotype is dominated by neurological/cognitive and behavioral features, superimposed on a profound but clinically "silent" biochemical abnormality.

Key supporting quotes: "A mentally retarded young woman with severe behaviour problems was found to excrete large amounts of glutathione due to a generalized gamma-glutamyl transpeptidase deficiency" PMID: 6118466; and the two molecularly confirmed siblings presented as "two siblings with mild psychomotor developmental delay and mild neurological symptoms, who presented a markedly increased excretion of glutathione in urine" PMID: 29483667. Two Japanese brothers showed retarded mental development and a tall slender (Marfan-like) habitus PMID: 15702405.

Phenotype characteristics. Onset is effectively congenital for the biochemical defect; clinical (cognitive/behavioral) features emerge in childhood. Severity is variable and generally mild in the genetically confirmed patients. Progression appears stable/non-progressive rather than degenerative, though natural-history data are essentially absent.

Quality-of-life impact. Not formally measured with any instrument (EQ-5D/SF-36/PROMIS). Impact is inferred to arise chiefly from the degree of intellectual disability and behavioral difficulties; the biochemical abnormality itself appears clinically well-tolerated.

4. Genetic / Molecular Information

Causal gene. GGT1 (HGNC:4250; NCBI Gene 2678; Ensembl ENSG00000100031), chromosome 22q11.23, GRCh38 chr22:24,594,811–24,629,005; canonical transcript ENST00000400382.

Pathogenic variants. - The index molecularly proven lesion is a 16.9 kb homozygous intragenic deletion (structural/copy-number variant) with a 13 bp insertion at the breakpoint — a loss-of-function allele requiring WGS/CNV analysis to detect (standard exome would likely miss it) PMID: 29483667. - Variant classification: pathogenic (biallelic LOF causing a loss-of-function disease). - Variant types expected across the disorder: structural deletions, and (by inference) nonsense/frameshift/splice/missense LOF alleles. - Somatic vs germline: germline. - Functional consequence: loss of function (absent enzyme activity).

gnomAD constraint (v2). Observed/expected LOF = 21/56 (oe_lof 0.375; 90% CI 0.27–0.54), pLI 0.82, missense Z 4.88 — GGT1 is relatively intolerant to heterozygous LOF, yet heterozygous carriers are clinically healthy, consistent with a recessive mechanism.

Protein and family. GGT belongs to the N-terminal nucleophile (Ntn) hydrolase superfamily. It is translated as a single-chain precursor that undergoes autocatalytic cleavage into a large and a small subunit, forming the mature, membrane-bound heterodimeric ectoenzyme; the N-terminal threonine of the small subunit (human hGGT1 Thr-381) is the catalytic nucleophile. "γ-Glutamyl transpeptidases (γ-GTs) are members of N-terminal nucleophile hydrolase superfamily. They are synthetized as single-chain precursors, which are then cleaved to form mature enzymes" PMID: 26536828; "Thr-381 is locked into a single conformation as an acyl bond forms between the substrate and the enzyme" PMID: 33187988.

Paralogs / redundancy. The human GGT family comprises 13 homologous genes (GGT1–7 and GGTLC1–3) on chromosomes 20 and 22: "The human GGT family comprises 13 homologous genes (e.g., GGT1-7 and GGTLC1-3) localized on chromosomes 20 and 22" PMID: 41316810 — a likely explanation for residual activity and the comparatively mild human phenotype.

Modifier genes / epigenetics / chromosomal abnormalities. No disease-specific modifier genes, epigenetic marks, or recurrent chromosomal abnormalities have been established for GGT deficiency. The causal lesion (structural deletion within 22q11.23) is itself a focal copy-number change but not a large cytogenetic abnormality.

Suggested ontology terms: HGNC:4250 (GGT1); GO:0036374 (glutathione hydrolase activity); GO:0006751 (glutathione catabolic process); CHEBI:16856 (glutathione).

5. Environmental Information

• Environmental factors: None established as causal or contributory to the inherited disease.
• Lifestyle factors: None established. Dietary cysteine/protein intake is a mechanistically plausible modifier of downstream cysteine deficiency (by analogy to cysteine supplementation rescuing mice), but this is not demonstrated in patients.
• Infectious agents: Not applicable — this is a Mendelian metabolic disorder with no infectious etiology or trigger.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function variants in GGT1 (e.g., 16.9 kb homozygous deletion) → loss of functional GGT protein on epithelial brush-border membranes (demonstrated in humans; PMID: 29483667).
2. Absent membrane-bound GGT → failure to hydrolyze extracellular/filtered glutathione at the renal proximal tubule brush border and other epithelia (demonstrated; PMID: 42531).
3. Failure of GSH breakdown → glutathione is not reclaimed and is lost in urine → glutathionuria + glutathionemia, with accumulation of γ-glutamylcysteine, cysteine and cysteinylglycine in plasma (demonstrated in humans; PMID: 15702405).
4. Loss of extracellular GSH → impaired cysteine salvage (GGT normally liberates cysteine for de novo intracellular GSH/protein synthesis) → intracellular cysteine deficiency (proven in mouse; inferred in human; PMID: 11089562).
5. Branch A (mouse, severe): Tissue cysteine/GSH depletion → growth failure, cataracts, lethargy, shortened lifespan; reproductive failure via suppressed IGF-1 and FSH; skeletal osteopenia/dwarfism via chondrocyte proliferation defect and osteoblast/osteoclast imbalance → all reversible with N-acetylcysteine / OTZ (proven in mouse; PMID: 12757858; PMID: 11089562; PMID: 12810527).
6. Branch B (human, mild): Residual cysteine supply (likely from paralogous GGT enzymes and dietary intake) limits systemic depletion → mild, mainly neurological/cognitive phenotype (intellectual disability, developmental delay, behavioral problems) rather than the severe mouse syndrome (inferred; PMID: 29483667; PMID: 41316810).

GGT1 biallelic LOF
      │
      ▼
Absent brush-border GGT ectoenzyme (kidney proximal tubule, etc.)
      │
      ▼
Extracellular/filtered glutathione NOT hydrolyzed
      │
      ├────────────► Urinary GSH loss ─► GLUTATHIONURIA + GLUTATHIONEMIA
      │                                   (↑ γ-glutamylcysteine, cysteine, cysteinylglycine)
      ▼
Impaired cysteine salvage ─► intracellular cysteine deficiency
      │
      ├── MOUSE (severe): growth failure, cataracts, infertility (↓IGF-1/↓FSH),
      │                   osteopenia  ── reversible by NAC / OTZ
      │
      └── HUMAN (mild): neurocognitive/behavioral phenotype
                        (buffered by GGT paralogs + diet)

Supporting detail by category

• Molecular pathways / biochemistry: The γ-glutamyl cycle / glutathione catabolism. GGT initiates extracellular GSH degradation, "hydrolyzing extracellular GSH and providing the cell with the recovery of cysteine, which is necessary for de novo intracellular GSH and protein biosynthesis" PMID: 37739139. KEGG: glutathione metabolism (map00480).
• Cellular processes: Redox homeostasis maintenance via cysteine supply; in mouse, chondrocyte proliferation and osteoblast/osteoclast balance are affected PMID: 12810527.
• Protein dysfunction: Complete loss of function of the Ntn-hydrolase ectoenzyme (no functional heterodimer formed).
• Metabolic changes: Disrupted glutathione and sulfur-amino-acid (cysteine) metabolism; "Tissue GSH deficiency is the proximate cause of the phenotypic abnormalities associated with murine gamma-GT deficiency" PMID: 12757858.
• Immune involvement: Not a feature of the inherited deficiency.
• Tissue damage mechanisms: Secondary to cysteine/GSH depletion (impaired antioxidant capacity) in mouse tissues.
• Biochemical abnormality: Enzyme deficiency — absent γ-glutamyl transpeptidase activity (<1 IU/L serum).
• Molecular profiling: No disease-specific transcriptomic/proteomic/metabolomic datasets exist for human patients beyond targeted metabolite measurements (elevated GSH and thiols).

Suggested ontology terms: GO:0006751 (glutathione catabolic process); GO:0036374 (glutathione hydrolase activity); GO:0006534 (cysteine metabolic process); GO:0006749 (glutathione metabolic process); CL:1000838 (kidney proximal convoluted tubule epithelial cell); CHEBI:16856 (glutathione); CHEBI:17561 (L-cysteine).

7. Anatomical Structures Affected

Organ level. - Primary site of metabolic lesion / GSH wasting: the kidney, specifically the proximal tubule brush border. "the enzyme is primarily associated with the luminal surface of the brush border membrane of the proximal straight tubule" PMID: 42531. - Clinically affected system (human): central nervous system / brain (cognitive and behavioral phenotype). - GGT is also expressed in other transport/secretory epithelia: "found in certain epithelial cells in anatomical sites that are involved in transport and secretory activities (e.g., renal tubule, jejunal villi, choroid plexus, ciliary body)" PMID: 45011 — hence biliary tract, jejunum, choroid plexus and ciliary body are enzyme-expressing sites. - Body systems involved: urinary (biochemical), nervous (clinical), and (in mouse) reproductive, skeletal, ocular.

Tissue and cell level. Epithelial tissue — chiefly renal proximal tubule epithelial cells (apical brush border). Suggested CL terms: CL:1000838 (kidney proximal convoluted tubule epithelial cell), CL:0000066 (epithelial cell).

Subcellular level. GGT is a plasma-membrane ectoenzyme anchored on the external/apical surface. Suggested GO cellular component: GO:0005886 (plasma membrane); GO:0016324 (apical plasma membrane); GO:0031526 (brush border membrane).

Localization. Suggested UBERON terms: UBERON:0001231 (nephron tubule) / UBERON:0004134 (proximal convoluted tubule); UBERON:0001088 (urine); UBERON:0000955 (brain). Lateralization is bilateral/systemic (the enzyme defect is generalized, not focal).

8. Temporal Development

• Onset: The biochemical defect is congenital; clinical (neurocognitive) features present in infancy/childhood. Onset pattern is insidious/chronic rather than acute.
• Progression: Appears stable/non-progressive based on the few reported cases; no staging system exists. Natural-history and longitudinal data are essentially absent.
• Disease course: Chronic, lifelong metabolic abnormality.
• Remission: No spontaneous remission of the biochemical defect; metabolic consequences are (in mouse) treatment-reversible with cysteine repletion.
• Critical periods: Not defined in humans; by analogy to mouse growth/reproductive phenotypes, childhood/developmental windows would be the plausible period for any metabolic intervention.

9. Inheritance and Population

Epidemiology. Ultra-rare. Fewer than ~8 patients have ever been reported worldwide; precise prevalence/incidence are unknown and almost certainly underestimated. "this condition has probably been underdiagnosed due the difficulty to routinely analyze glutathione in clinical samples" PMID: 29483667.

Genetic parameters. - Inheritance pattern: Autosomal recessive, now directly proven by segregation in a confirmed family: "genetic characterization of the patients' parents and a healthy sibling has provided direct genetic evidence regarding the autosomal recessive nature of this disease" PMID: 29483667. - Penetrance/expressivity: The biochemical phenotype appears fully penetrant; the neurological phenotype shows variable expressivity and uncertain penetrance given tiny numbers. More broadly for γ-glutamyl cycle disorders: "All disorders are very rare and inherited in an autosomal recessive manner. Most of the mutations are leaky so that many patients have residual enzyme activity" PMID: 17397529. - Genetic anticipation: Not applicable (not a repeat-expansion disorder). - Germline mosaicism / founder effects: None documented. - Consanguinity: Homozygosity for a structural deletion in the index family is consistent with a role for shared ancestry/consanguinity, as is typical of rare AR disease, though not explicitly characterized. - Carrier frequency: Unknown; cannot be reliably estimated from gnomAD for a disease defined largely by structural variants.

Population demographics. No ethnic predilection established (reported cases include European and Japanese patients PMID: 15702405). No defined geographic clustering, sex ratio, or age distribution given the few cases.

10. Diagnostics

Diagnostic approach. Diagnosis rests on the biochemical demonstration of glutathionuria + glutathionemia together with very low/absent serum and tissue GGT activity (<1 IU/L), confirmed by GGT1 sequencing PMID: 15702405; PMID: 6118466.

Clinical/laboratory tests. - Quantitative urine and plasma glutathione (markedly elevated), plus γ-glutamylcysteine, cysteine, cysteinylglycine. "Glutathionaemia and glutathionuria were evident in both brothers. The analyses of sulphydryl compounds in the plasma ... and urine indicated high concentrations of glutathione, gamma-glutamylcysteine, cysteine and cysteinylglycine" PMID: 15702405. - Serum GGT enzyme activity (very low/undetectable). LOINC: serum GGT activity (e.g., LOINC 2324-2). - Diagnostic pitfall: on routine amino-acid chromatography, thiol compounds produce "a large peak in the citrulline position," which can mislead — "Urine amino acid analysis on an automatic analyser showed a slightly increased excretion of cystine and a large peak in the citrulline position due, at least in part, to thio-compounds" PMID: 15702405.

Genetic testing. GGT1 sequencing is confirmatory. Because the index lesion was a 16.9 kb structural deletion, WGS or CNV/deletion-duplication analysis may be required — standard whole-exome sequencing can miss such events PMID: 29483667. Single-gene testing or a metabolic gene panel including GGT1 is appropriate; chromosomal microarray may detect larger deletions.

Omics-based diagnostics. Targeted metabolomics (thiol/glutathione quantification by HPLC/LC-MS) is effectively the functional diagnostic test; no transcriptomic/proteomic diagnostic is established.

Clinical criteria / differential diagnosis. No formal consensus diagnostic criteria exist. Differential diagnosis includes other γ-glutamyl cycle / glutathione-metabolism disorders (e.g., glutathione synthetase deficiency / 5-oxoprolinuria, γ-glutamylcysteine synthetase deficiency) — distinguished by their specific metabolite patterns and enzyme assays PMID: 17397529. The citrulline-position peak also raises a spurious concern for a urea-cycle abnormality that must be excluded.

Screening. Not included in standard newborn screening because glutathione is not measured in routine metabolic panels PMID: 29483667. Cascade/carrier testing is feasible once a family's GGT1 variant is known.

11. Outcome / Prognosis

• Survival/mortality: No evidence of reduced survival in reported human patients; the biochemical abnormality appears compatible with normal life span. (Mouse knockouts, by contrast, have shortened life spans.)
• Morbidity/function: Driven by the neurocognitive phenotype — intellectual disability and behavioral difficulties account for functional impact. No validated QoL data.
• Disease course/complications: Chronic and apparently non-progressive; no characteristic organ-failure complications documented in humans.
• Recovery potential: The genetic/biochemical defect is permanent. Downstream metabolic consequences are, in principle, modifiable (mouse data), but human cognitive outcomes are not known to be reversible.
• Prognostic factors/biomarkers: None validated. Degree of intellectual disability is the main determinant of outcome in reported cases; true genotype–phenotype correlations cannot be drawn from <8 patients.

12. Treatment

There is no approved disease-specific pharmacotherapy; human management is supportive. No targeted, gene, cell, RNA, immunologic or surgical therapy exists.

Rational (mechanism-based, mouse-validated) strategy — cysteine repletion. In Ggt-deficient mice, supplying an alternative cysteine source corrects the downstream phenotype: - N-acetylcysteine (NAC) restores gonad size, hormone levels and fertility, and ameliorates skeletal abnormalities: "N-acetylcysteine treatment of GGT-/- mice ameliorates their skeletal abnormalities by normalizing chondrocytes proliferation and osteoblastic function" PMID: 12810527; reproductive rescue PMID: 11089562. Suggested NCIT: Acetylcysteine (NCIT:C28159). - L-2-oxothiazolidine-4-carboxylate (OTZ / procysteine), a cysteine prodrug, partially restores liver GSH and improves growth/behavior in mice PMID: 12757858.

These approaches are not formally trialed in human patients — they represent a biologically rational but unproven therapeutic avenue for humans.

Supportive/rehabilitative care. Developmental, educational and behavioral support for intellectual disability and behavioral problems, as for other causes of neurodevelopmental impairment.

Pharmacogenomics / personalized medicine: Not applicable beyond genotype-confirmed diagnosis guiding counseling.

13. Prevention

• Primary prevention: Not possible for a Mendelian disorder; relies on genetic counseling and reproductive options for at-risk couples.
• Secondary prevention / early detection: Not currently part of newborn screening (glutathione is not routinely measured) PMID: 29483667. Targeted glutathione measurement should be considered in unexplained intellectual disability with abnormal amino-acid chromatography (the citrulline-position pitfall).
• Tertiary prevention: Mechanistically, cysteine repletion (NAC/OTZ) could in theory prevent downstream metabolic complications, extrapolating from mouse data; unproven in humans.
• Genetic screening/counseling: Once a family's GGT1 variant(s) are known, carrier testing, cascade screening, prenatal and preimplantation genetic testing are feasible. Genetic counseling (25% recurrence risk per pregnancy for carrier couples) is the mainstay of prevention.
• Immunization / public-health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Taxonomy: Best-characterized outside humans in the house mouse (Mus musculus; NCBI Taxon 10090).
• Orthologous gene: mouse Ggt1 (NCBI Gene 14598; MGI).
• Natural disease: No well-documented naturally occurring GGT1-deficiency disease in companion animals or wildlife is recorded in the knowledge base; the mouse disease is experimentally induced (ENU mutagenesis or targeted knockout), not naturally arising.
• Comparative biology: The mouse recapitulates the core metabolic lesion (glutathionuria, glutathionemia, reduced liver GSH) well, but is far more severe than human disease — a key cross-species difference likely reflecting human GGT paralog redundancy (13 family genes; PMID: 41316810) and species differences in GSH handling.
• Evolutionary conservation: The Ntn-hydrolase GGT mechanism is deeply conserved from bacteria to mammals PMID: 26536828.
• Transmission / zoonosis: Not applicable (non-infectious genetic disease).

15. Model Organisms

Principal models — mouse. Two mouse models are the main disease models: 1. ENU-induced GGTenu1 mutant, discovered via aminoaciduria screening: "A mouse mutant with glutathionuria was discovered by screening for amino acidurias in the progeny of ethylnitrosourea-mutagenized mice" PMID: 9139708. 2. Targeted Ggt1 knockout (Lieberman lab) PMID: 11089562; PMID: 12810527.

Model characteristics / phenotype recapitulation. Both reproduce the biochemistry faithfully: autosomal-recessive glutathionuria/glutathionemia, reduced liver GSH. Additional (more severe than human) features: growth failure, cataracts, coat-color defects, lethargy, infertility, osteopenia/dwarfism, and shortened life span PMID: 9139708; PMID: 12757858. Reproductive failure is attributed to intracellular cysteine deficiency: mice are "growth retarded as a result of cysteine deficiency secondary to excessive glutathione excretion in urine" PMID: 11089562.

Model limitations. The mouse is more severe than human disease and does not model the predominantly mild neurocognitive human phenotype — a discrepancy attributed to paralog redundancy and species GSH-handling differences.

Applications. The models established the proximate mechanism (tissue GSH/cysteine deficiency) and therapeutic reversibility (NAC/OTZ), underpinning the rational treatment hypothesis for humans.

Resources: MGI (mouse Ggt1, Gene 14598). No established zebrafish/Drosophila/C. elegans/organoid disease models are recorded for this condition in the knowledge base.

Mechanistic Model / Interpretation

The disease is best understood as a failure of the salvage arm of the glutathione (γ-glutamyl) cycle. Glutathione synthesized intracellularly (predominantly in liver) is exported to plasma and filtered at the glomerulus; the renal proximal-tubule brush-border GGT normally hydrolyzes this extracellular GSH, releasing amino acids (notably cysteine) for reuptake and reuse. When GGT1 is lost, this salvage step fails: glutathione cannot be reclaimed and spills into urine (glutathionuria) while accumulating in plasma (glutathionemia), and the cell is deprived of recovered cysteine.

Whether that cysteine deprivation becomes clinically significant depends on how much redundant/alternative cysteine supply remains. In mice — with the sharpest metabolic dependence and (apparently) less effective buffering — systemic cysteine/GSH depletion produces a severe, multisystem, life-shortening phenotype that is fully bypassable by feeding cysteine (NAC) or a cysteine prodrug (OTZ). In humans, the presence of 13 GGT-family paralogs plus dietary cysteine appears to buffer systemic cysteine supply, so the phenotype is limited to a mild, chiefly neurocognitive presentation. This two-branch model (identical upstream lesion; divergent downstream severity set by cysteine-supply redundancy) reconciles the dramatic human biochemistry with the surprisingly benign human clinical course, and it directly motivates cysteine-repletion therapy as the rational — though still unproven in humans — intervention.

Evidence Base

Consistency. The findings are internally consistent: physiologic localization studies (brush border; PMID: 42531) explain the urinary-loss phenotype; pharmacologic inhibition experiments (PMID: 34150; PMID: 2873573) phenocopy the inherited defect; mouse genetics (PMID: 11089562; PMID: 12757858; PMID: 12810527) establish causality and reversibility; and human genetics (PMID: 29483667) confirm the gene and inheritance. The main tension in the evidence base is the severity mismatch between mouse and human, addressed by the paralog-redundancy hypothesis.

Limitations and Knowledge Gaps

1. Tiny human sample (<8 patients): prevalence, penetrance, expressivity, sex ratio, and genotype–phenotype correlations cannot be reliably estimated.
2. Mechanism in humans is inferred: cysteine depletion as the proximate cause and NAC/OTZ reversibility are proven only in mice; never formally demonstrated or trialed in human patients.
3. No validated biomarkers of prognosis and no natural-history studies.
4. Causal spectrum incomplete: only a structural deletion is molecularly proven; the full allelic spectrum (point mutations) and carrier frequency remain undefined; structural variants may be missed by standard exome sequencing.
5. Species discrepancy unresolved at the molecular level: the paralog-redundancy explanation is plausible but not directly tested.
6. No disease-specific therapy is approved or trialed in humans.
7. Under-ascertainment: glutathione is not in standard screens, so the true disease burden is unknown.

Proposed Follow-up Experiments / Actions

1. International case finding / registry: Prospectively measure urine and plasma glutathione in unexplained intellectual disability with the "citrulline-position" chromatographic peak; aggregate cases to estimate prevalence and phenotype spectrum.
2. Define the GGT1 allelic spectrum: Apply WGS/CNV-aware pipelines (not exome alone) in suspected cases to catalog point and structural variants; estimate carrier frequency from large population datasets with structural-variant calling.
3. Test the cysteine-depletion mechanism in humans: Measure intracellular/erythrocyte cysteine and GSH in confirmed patients; correlate with clinical severity.
4. Pilot cysteine-repletion therapy: Given mouse reversibility and NAC's established safety, consider an n-of-1 or small compassionate-use trial of NAC/OTZ with biochemical (plasma/urine GSH, cysteine) and developmental endpoints.
5. Interrogate paralog redundancy: Quantify residual GGT activity from paralogs (GGT5, etc.) in patient tissues/iPSC-derived cells; model double-paralog loss to test the severity-buffering hypothesis.
6. Improve the human-relevant model: Engineer humanized or paralog-sensitized mouse/organoid models that reproduce the mild human neurocognitive phenotype for mechanism and therapy testing.
7. Ontology/knowledge-base annotation: Finalize mappings (MONDO:0009285; GGT1/HGNC:4250; HP:0001249, HP:0001263, HP:0000708; GO:0006751/GO:0036374; UBERON proximal tubule; CHEBI:16856 glutathione; NCIT:C28159 acetylcysteine) for the disease entry.

Evidence source legend: Human clinical = case reports/series (PMID: 29483667, 15702405, 6118466, 238530); Model organism = mouse (PMID: 9139708, 11089562, 12757858, 12810527); In vitro/structural (PMID: 33187988, 26536828); Reviews (PMID: 37739139, 17397529, 41316810).

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:26536828 (7 mentions) - The maturation mechanism of γ-glutamyl transpeptidases: Insights from the crystal structure of a precursor mimic of the enzyme from Bacillus licheniformis and from site-directed mutagenesis studies.
• shared terms: enzyme, genetic

Weighed against this report's own most characteristic terms: human, disease, cysteine, glutathione, phenotype, ggt, mouse, deficiency, ggt1, gsh, glutathionuria, biochemical, patient, metabolic, enzyme, gene, genetic, otz, activity, clinical.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0009285 (3 mentions) - the report calls it "MONDO"; MONDO calls it gamma-glutamyl transpeptidase deficiency
• HP:0001249 (2 mentions) - the report calls it "Clinical sign"; HP calls it Intellectual disability
• HP:0001263 (2 mentions) - the report calls it "Clinical sign"; HP calls it Global developmental delay

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0006534 (obsolete cysteine metabolic process) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000708 (2 mentions) - the report calls it "Behavioral"; HP calls it Atypical behavior, and lists "Behavioral changes" among its other names
• HP:0000707 (1 mention) - the report calls it "abnormality of nervous system"; HP calls it Abnormality of the nervous system
• GO:0036374 (3 mentions) - the report calls it "glutathione hydrolase activity"; GO calls it glutathione gamma-glutamate hydrolase, and lists "glutathione hydrolase activity" among its other names
• GO:0006534 (1 mention) - the report calls it "cysteine metabolic process"; GO calls it obsolete cysteine metabolic process
• UBERON:0004134 (1 mention) - the report calls it "proximal convoluted tubule"; UBERON calls it proximal tubule, and lists "proximal kidney tubule" among its other names